Semaglutide 2.4 mg injection (Wegovy , Novo Nordisk ), a glucagon-like peptide-1 (GLP-1) receptor agonist, was approved in June 2021 for chronic weight management in adults with overweight and 1 weight-related condition or obesity based on demonstrated weight reduction in clinical trials [10]
Yet the race is on for the next generation, and we explore 10 promising new drugs in development
GLP3 Mechanism of Action GLP3 peptide exerts its biological effects through balanced activation of three G-protein-coupled receptors that collectively regulate metabolic homeostasis
Consequently, it is impossible to determine whether IN GHK-Cu restored the aged hippocampus to a younger baseline, or if it simply pushed the tissue into a novel, alternative compensatory state that functions better in a spatial maze
It doesnt cure aging (nothing does), but it appears to modulate several pathways that otherwise accelerate it